Levosimendan Stada (Levosimendan)

Levosimendan works by binding to troponin C in heart muscle cells, which makes the contractile proteins more sensitive to calcium, thereby strengthening heart contractions without raising calcium levels. It also opens ATP‑sensitive potassium channels in blood vessels, causing vasodilation and lowering the workload on the heart.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response to therapy. The medication is administered intravenously under continuous monitoring, and the prescriber sets the infusion rate and duration.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of calcium‑mediated arrhythmias. It also provides vasodilation through potassium‑channel activation, offering combined inotropic and afterload‑reducing effects that differ from agents such as dobutamine or milrinone.

Levosimendan Stada should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Levosimendan is given as an intravenous infusion, typically started with a loading dose followed by a continuous maintenance infusion. Administration is performed in a setting where cardiac monitoring is available, such as an intensive care unit or cardiac care unit.

The most serious risks include severe hypotension, ventricular arrhythmias, and myocardial ischemia. Patients should be closely monitored for blood pressure changes, rhythm disturbances, and signs of reduced coronary perfusion throughout the infusion.

Levosimendan should be avoided in patients with known hypersensitivity to the drug, uncontrolled severe hypotension, or those receiving other potent vasodilators that could precipitate dangerous blood pressure drops. Caution is also advised in severe hepatic impairment and in patients with significant ventricular arrhythmias.